ストックスクリーナーアプリを入手
9.10
5.60%
-0.54
アフターアワーズ：
9.32
0.22
+2.42%
Karyopharm Therapeutics Inc (KPTI) 最新ニュース
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - TradingView
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - GlobeNewswire Inc.
Karyopharm Therapeutics secures EHA Congress acclaim for late-breaking SENTRY trial update - Traders Union
Cantor Fitzgerald reiterates Overweight on Karyopharm stock - Investing.com UK
Cantor Fitzgerald reiterates Overweight on Karyopharm stock By Investing.com - Investing.com South Africa
How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI) - Yahoo Finance
T. Rowe Price (KPTI) files Schedule 13G/A showing 6.6% position - Stock Titan
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 - Karyopharm
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-06-02 - Seeking Alpha
KPTI: Karyopharm's Abstract Accepted for Presentation at Europea - GuruFocus
KPTI: Karyopharm Announces Positive Phase 3 SENTRY Trial Results - GuruFocus
KPTI: Selinexor plus ruxolitinib nearly doubled spleen response and improved survival in myelofibrosis - TradingView
Karyopharm reports phase 3 myelofibrosis trial results at ASCO - Investing.com UK
Karyopharm reports phase 3 myelofibrosis trial results at ASCO By Investing.com - Investing.com Nigeria
Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis - marketscreener.com
Karyopharm’s myelofibrosis trial selected for EHA presentation By Investing.com - Investing.com South Africa
Karyopharm’s myelofibrosis trial selected for EHA presentation - Investing.com UK
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 - Karyopharm
Cancer trial suggests spleen shrinkage may predict survival in myelofibrosis - Stock Titan
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology - Karyopharm
Karyopharm Therapeutics Presents Results from Phase 3 Sentry Trial of Selinexor Plus Ruxolitinib in Myelofibrosis - marketscreener.com
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Karyopharm Therapeutics (KPTI) to Discuss SENTRY Trial Results i - GuruFocus
Karyopharm to host call on phase 3 myelofibrosis trial results By Investing.com - Investing.com Australia
Karyopharm to host call on phase 3 myelofibrosis trial results - Investing.com
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation - Karyopharm
Myelofibrosis Phase 3 trial data to be detailed on June 2 call - Stock Titan
KPTI Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Absence, Stock DipsQuarterly Profit Report - newsline.com
Karyopharm shares rise 10% after mixed Phase 3 SENTRY trial results - MSN
Karyopharm Therapeutics (KPTI) Holds Near $9.10 Amid Low-Volume ConsolidationPercent Below MA - newsline.com
KPTI News | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill
Karyopharm (NASDAQ: KPTI) boosts share plans and grants CEO PSU awards - Stock Titan
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference - Karyopharm
Karyopharm to Speak at 2026 Jefferies Global Healthcare Conference - Intellectia AI
Cancer drug maker Karyopharm joins 2026 Jefferies healthcare summit - Stock Titan
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet - Yahoo Finance
Karyopharm (KPTI) director Christy Oliger receives 15,508 RSU equity award - Stock Titan
Karyopharm (KPTI) director awarded 15,508 RSUs vesting in 2027 - Stock Titan
Chen Schor of Karyopharm (KPTI) receives 15,508 RSU award - Stock Titan
Karyopharm Therapeutics (KPTI) director receives 15,508 RSUs in equity award - Stock Titan
Karyopharm (KPTI) director receives 15,508 RSU equity award vesting in 2027 - Stock Titan
Karyopharm (NASDAQ: KPTI) director gets 15,508 RSUs vesting in 2027 - Stock Titan
Karyopharm Therapeutics spotlights selinexor milestones, ASCO data and cancer trial readouts - MSN
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts - Barchart
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):